Microbiome’s Moment Approaches: Finch Joins Rival C Diff Companies
Infection Is Common Killer
Executive Summary
After a trial failure in 2016, four rival companies could produce pivotal data this year
You may also be interested in...
Pfizer Holds Out Hope For C. Diff Vaccine Despite Clinical, Commercial Failures
Pfizer’s Clostridioides difficile vaccine candidate missed a Phase III primary endpoint but the company may seek a path forward based on secondary endpoints even after past failures in the field.
Summit's Lead Antimicrobial Fails Pivotal Study, May Spark Therapeutic Shift
Ridinilazole fell short of significance in a late-stage trial, with some analysts now anticipating the company will alter its therapeutic strategy entirely.
Finance Watch: Biopharma IPOs Regain Momentum With Slate Of New Offerings
Public Company Edition: Instil Bio, Connect Biopharma, Finch Therapeutics, Gain Therapeutics and four heath care-focused SPACs launched initial public offerings; Endo raised $1.3bn via note sale; and Rubius Therapeutics, Solid Biosciences and others priced follow-on offerings.